Nasdaq:US$13.39 (+1.18) | HKEX:HK$19.86 (-0.29) | AIM:£2.09 (-0.1)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.